Clinical trialPhase 1 / Phase 2Unknown
Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer
- Outcome
- Outcome unknown
- Cell product
- Other cell therapies
Other: iAPA-DC/CTL adoptive cellular immunotherapy
- Phase
- Phase 1 / Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- June 2015
- Listed end
- December 2019
- Enrollment
- 187 participants
- Sites
- 1
- Primary outcomes
- 6-month SR
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 20 August 2015
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The aim of this study is to evaluate the safety and efficacy of iAPA-DC/CTL combined gemcitabine therapy on advanced pancreatic cancer.
Intervention public domain (ClinicalTrials.gov)
Other: iAPA-DC/CTL adoptive cellular immunotherapy. twice DC cell infusion and CTL cell infusion for 6 times
Intervention public domain (ClinicalTrials.gov)
Drug: Gemcitabine. standard Gemcitabine therapy
Arm public domain (ClinicalTrials.gov)
Gemcitabine (active comparator): Standard Gemcitabine Therapy
Arm public domain (ClinicalTrials.gov)
cellular immunotherapy & Gemcitabine (experimental): iAPA-DC/CTL adoptive cellular immunotherapy combined Standard Gemcitabine Therapy
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria: 1. Advanced Pancreatic cancer patients with histological pathology confirmation 2. Both gender, aged 18-70 year-old 3. Bone marrow functioned well 4. Renal function normal 5. Liver function normal 6. patients are voluntary, and willing to sign informed consent 7. expected lifetime was at least 3 months Exclusion Criteria: 1. With acute inflammation 2. Accompanied with primary malignant tumor other than pancreas 3. with autoimmune disease 4. using corticosteroid or other suppress immune hormone treatment 5. had transplant operation of vital organs 6. active hepatitis 7. HIV positive 8. dysfunction in blood coagulation 9. serious diseases in circulatory and respiratory systems 10. pregnancy or breast-feeding women